Valentina de Murtas

Valentina de Murtas

Auto-generated profile, based on publicly available information

Valentina de Murtas

IRCCS Humanitas Research Hospital 1 Department of Gastroenterology, Laboratory of Molecular Gastroenterology Rozzano, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
SLSusie A. Lee
Susie A. Lee
SLSara Ladu
Sara Ladu
MEMatthias Evert
Matthias Evert
FDFrank Dombrowski
Frank Dombrowski
VMValentina De Murtas
Valentina De Murtas
DCDiego Francesco Calvisi
Diego Francesco Calvisi
Sprouty2 (Spry2), a negative feedback regulator of the Ras/mitogen‐activated protein kinase (MAPK) pathway, is frequently down‐regulated in human hepatocellular carcinoma (HCC). We tested the hypothesis that loss of Spry2 cooperates with unconstrained activation of the c‐Met protooncogene to induce hepatocarcinogenesis via in vitro and in vivo approaches. We found coordinated down‐regulation of Spry2 protein expression and activation of c‐Met as well as its downstream effectors extracellular signal‐regulated kinase (ERK) and v‐akt murine thymoma viral oncogene homolog (AKT) in a subset of human HCC samples with poor outcome. Mechanistic studies revealed that Spry2 function is disrupted in human HCC via multiple mechanisms at both transcriptional and post‐transcriptional level, including promoter hypermethylation, loss of heterozygosity, and proteosomal degradation by neural precursor cell expressed, developmentally down‐regulated 4 (NEDD4). In HCC cell lines, Spry2 overexpression inhibits c‐Met–induced cell proliferation as well as ERK and AKT activation, whereas loss of Spry2 potentiates c‐Met signaling. Most importantly, we show that blocking Spry2 activity via a dominant negative form of Spry2 cooperates with c‐Met to promote hepatocarcinogenesis in the mouse liver by sustaining proliferation and angiogenesis. The tumors exhibited high levels of activated ERK and AKT, recapitulating the subgroup of human HCC with a clinically aggressive phenotype. Conclusion: The occurrence of frequent genetic, epigenetic, and biochemical events leading to Spry2 inactivation provides solid evidence that Spry2 functions as a tumor suppressor gene in liver cancer. Coordinated deregulation of Spry2 and c‐Met signaling may be a pivotal oncogenic mechanism responsible for unrestrained activation of ERK and AKT pathways in human hepatocarcinogenesis. (HEPATOLOGY 2010)

21 November 2010 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
AZAngelo Zinellu
Angelo Zinellu
SSSalvatore Sotgia
Salvatore Sotgia
VMValentina De Murtas
Valentina De Murtas
PCPaolo Cossu-Rocca
Paolo Cossu-Rocca
Maria Rosaria De MiglioMaria Rosaria De Miglio
Maria Rosaria De Miglio
Ciriaco CarruCiriaco Carru
Ciriaco Carru

25 February 2024 in Medicina
Verified
Journal Article
Open access
PDF file
GIANPAOLO VIDILIGIANPAOLO VIDILI
GIANPAOLO VIDILI
AZAngelo Zinellu
Angelo Zinellu
Arduino MangoniArduino Mangoni
Arduino Mangoni
MAMARCO ARRU
MARCO ARRU
VMValentina De Murtas
Valentina De Murtas
Panagiotis PaliogiannisPanagiotis Paliogiannis
Panagiotis Paliogiannis
Background and Objectives. Hepatocellular carcinoma (HCC) and the intrahepatic biliary tract cancers are estimated to rank sixth for incidence among solid cancers worldwide, and third for mortality rates. A critical issue remains the need for accurate biomarkers for risk stratification and overall prognosis. The aim of this study was to investigate the ability of a biomarker of heterogeneity of the size of red blood cells, the red cell distribution width (RDW), to predict survival in patients with HCC. Materials and Methods. A consecutive series of patients with a histologic diagnosis of HCC were included into this study irrespective of their age, stage of the disease, and treatment administered, and followed-up for a period of three years. Demographic, anthropometric [age, sex, body mass index (BMI)], and clinical data (Charlson Comorbidity Index, Child–Pugh score, etc.), along with laboratory tests were retrieved from clinical records. Results. One-hundred and four patients were included in this study. Among them, 54 (69%) were deceased at the end of the follow-up. Higher RDW values, but not other hematological and biochemical parameters, were significantly associated with mortality in both univariate and multivariate analysis. The optimal RDW cut-off value identified with the Youden test for survival was 14.7%, with 65% sensitivity and 74% specificity (AUC = 0.718, 95% CI 0.622–0.802, p < 0.001). Kaplan–Meier survival curves showed significantly lower survival with higher RDW values (HR = 3.5204; 95% CI 1.9680–6.2975, p < 0.0001) with a mean survival of 30.9 ± 9.67 months for patients with RDW ≤ 14.7% and 22.3 ± 11.4 months for patients with RDW > 14.7%. Conclusions. The results of our study showed that RDW can perform better than other blood-based biomarkers in independently predicting prognosis in patients with HCC.

23 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MAMohammad Alkhatib
Mohammad Alkhatib
VMVelia Chiara Di Maio
Velia Chiara Di Maio
VMValentina De Murtas
Valentina De Murtas
EPEnnio Polilli
Ennio Polilli
MMMartina Milana
Martina Milana
ORon behalf of HIRMA (Hepatocarcinoma Innovative Research MArkers) and Fondazione Vironet C (HCV Virology Italian Resistance
on behalf of HIRMA (Hepatocarcinoma Innovative Research MArkers) and Fondazione Vironet C (HCV Virology Italian Resistance
HCV is an important cause of hepatocellular carcinoma (HCC). HCV NS5A domain-1 interacts with cellular proteins inducing pro-oncogenic pathways. Thus, we explore genetic variations in NS5A domain-1 and their association with HCC, by analyzing 188 NS5A sequences from HCV genotype-1b infected DAA-naïve cirrhotic patients: 34 with HCC and 154 without HCC. Specific NS5A mutations significantly correlate with HCC: S3T (8.8% vs. 1.3%, p = 0.01), T122M (8.8% vs. 0.0%, p < 0.001), M133I (20.6% vs. 3.9%, p < 0.001), and Q181E (11.8% vs. 0.6%, p < 0.001). By multivariable analysis, the presence of >1 of them independently correlates with HCC (OR (95%CI): 21.8 (5.7–82.3); p < 0.001). Focusing on HCC-group, the presence of these mutations correlates with higher viremia (median (IQR): 5.7 (5.4–6.2) log IU/mL vs. 5.3 (4.4–5.6) log IU/mL, p = 0.02) and lower ALT (35 (30–71) vs. 83 (48–108) U/L, p = 0.004), suggesting a role in enhancing viral fitness without affecting necroinflammation. Notably, these mutations reside in NS5A regions known to interact with cellular proteins crucial for cell-cycle regulation (p53, p85-PIK3, and β-catenin), and introduce additional phosphorylation sites, a phenomenon known to ameliorate NS5A interaction with cellular proteins. Overall, these results provide a focus for further investigations on molecular bases of HCV-mediated oncogenesis. The role of theseNS5A domain-1 mutations in triggering pro-oncogenic stimuli that can persist also despite achievement of sustained virological response deserves further investigation.

1 October 2026
Verified
Other
Open access
PDF file
Federica RubbinoFederica Rubbino
Federica Rubbino
LGLuana Greco
Luana Greco
ASAlessandro Scagliotti
Alessandro Scagliotti
Alessio Di CristofaroAlessio Di Cristofaro
Alessio Di Cristofaro
VMValentina de Murtas
Valentina de Murtas
LLLuigi Laghi
Luigi Laghi
Representative hematoxylin and eosin (H&E) staining of murine pancreatic tissue from KC WT and h67d mice at different ages. Red boxes indicate selected regions of interest, labeled as 1, 2, and 3.

1 October 2026
Verified
Other
Open access
PDF file
Federica RubbinoFederica Rubbino
Federica Rubbino
LGLuana Greco
Luana Greco
ASAlessandro Scagliotti
Alessandro Scagliotti
Alessio Di CristofaroAlessio Di Cristofaro
Alessio Di Cristofaro
VMValentina de Murtas
Valentina de Murtas
LLLuigi Laghi
Luigi Laghi
(A) H&E sections of Visium-analyzed tumor biopsies, with circles indicating tumoral areas, including the tumor-stroma interface, as marked by the pathologist for WT, non-carriers (top) and H63D (bottom) samples. (B) H&E slices with selected spots mapped and color-coded according to tissue morphology. (C) GSEA enrichment plots showing the running scores for EMT and the G2M phase checkpoint.